Joanne Billings, MD
Pulmonary Disease · Minneapolis, MNNPI 1275579583
Payments from drug & device makers
What this record shows
This record is dominated by education: $32 of the $32 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, Insmed, Inc.. That places this record below the midpoint for pulmonary disease clinicians in MN, where the typical reported total is $128.
Across 2 payments — averaging $16.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insmed, Inc.$32
Across 42 payments — averaging $34,969 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$1.5M
- AbbVie$10K
- Vivus LLC$1K
What the payments were for
- Education$32100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insmed, Inc. | 2 | $32 |
How this compares
$32 in reported general payments places this provider in the 30th percentile of 261 pulmonary disease providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrikaftaElexacaftor/Tezacaftor/Ivacaft | 130 | $3,550,308 |
| ZenpepLipase/Protease/Amylase | 21 | $255,271 |
| CreonLipase/Protease/Amylase | 36 | $232,810 |
| Aztreonam | 18 | $23,125 |
| ColistimethateColistin (Colistimethate Na) | 22 | $15,195 |
| Meropenem | 24 | $6,929 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $4,257 |
| Ursodiol | 27 | $964 |
| Ventolin HfaAlbuterol Sulfate | 14 | $803 |
| Azithromycin | 54 | $726 |
| Pantoprazole Sodium | 26 | $404 |
| Omeprazole | 22 | $238 |
| Fluticasone Propionate | 13 | $218 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 27 | $179 |
| Montelukast Sodium | 28 | $150 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Minneapolis
- Marshall HertzMinneapolis$289K
- David IngbarMinneapolis$272K
- Jonathan HovdaMinneapolis$139K
- Hyun KimMinneapolis$77K
- Grady HedstromMinneapolis$50K
- Joseph KeenanMinneapolis$37K
- Mitchell KayeMinneapolis$24K
- Jennifer WongMinneapolis$12K
- Patrick WrightMinneapolis$10K
- Abdallah AbboudMinneapolis$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.